Core Viewpoint - Boston Scientific is significantly expanding its localization strategy in China, leveraging the China International Import Expo (CIIE) to showcase innovative products and establish a strong foothold in the local market [2][3]. Group 1: Localization Strategy - Boston Scientific has achieved a "triple jump" in localization over six years, transitioning from an importer to a local manufacturer with its own factory in Shanghai [3][5]. - The company has successfully utilized the Medical Device Registration Holder (MAH) system to facilitate local production, exemplified by the Polaris intravascular ultrasound system, which received its first domestic registration certificate in July 2022 [6][7]. - In 2023, Boston Scientific made a strategic investment in the Chinese medical device company Xianruida, enhancing its integration into the local supply chain and expanding its product offerings [7][8]. Group 2: Product Development and Innovation - At the 2023 CIIE, Boston Scientific showcased four unreleased products, all set to be manufactured at its Shanghai factory, marking a significant step in its localization efforts [3][10]. - The AVVIGO+ intravascular ultrasound diagnostic system, a complex product developed with significant input from the Chinese team, demonstrates the company's commitment to local innovation [14][16]. - The Shanghai Lingang factory is designed to meet both Chinese and international standards, aiming to become a leading smart factory for Boston Scientific globally [7][8]. Group 3: Market Potential and Collaboration - The Chinese market is viewed as one of the most attractive and promising markets for Boston Scientific, driven by local supply chain advantages and increasing R&D capabilities [12][16]. - The company is actively engaging with local partners and government bodies to explore collaborative opportunities and enhance the local medical industry [15][17]. - Boston Scientific aims to better serve local patients by continuously introducing products and accelerating its localization process [17].

Group 1 - The core viewpoint of the article highlights the significance of technological innovation as a driving force for high-quality development in the healthcare industry, with a focus on the achievements of YOUMAGIC Shuliti R&D Company and its subsidiary Weimai Medical [3][5] - YOUMAGIC Shuliti R&D Company has established a strong foundation in scientific research, leveraging over 30 years of RF technology experience from Tsinghua University's Engineering Physics Department and nearly 70 years of high-energy physics research to enhance its technological innovation capabilities [3][5] - The company has developed a comprehensive product line in both serious medical and consumer healthcare sectors, with multiple products receiving NMPA Class III certification, indicating its potential for high-energy development [3][5] Group 2 - YOUMAGIC Shuliti R&D Company has demonstrated a keen market insight, adapting to the trends of "precision medicine" and the widespread application of AI technology in the healthcare sector, which is reshaping the industry landscape [5][7] - The company's flagship product, the YOUMAGIC Shuliti next-generation high-energy monopolar RF device, is the first in China to receive both NMPA and FDA dual certification, catering to diverse consumer treatment needs with customizable treatment plans [5][7] - Future plans for YOUMAGIC Shuliti include deepening its focus on precision medicine, accelerating the development of a multi-head product matrix, and enhancing the application of AI technologies in healthcare to provide better, more precise, and comfortable medical solutions globally [7]